Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
COL-PROBENECID vs PROBENECID AND COLCHICINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Colchicine binds to tubulin, inhibiting microtubule polymerization and reducing inflammatory cell chemotaxis. Probenecid inhibits renal tubular reabsorption of uric acid, increasing uric acid excretion and lowering serum urate levels.
Probenecid inhibits renal tubular reabsorption of uric acid, increasing its excretion; colchicine binds to tubulin, inhibiting microtubule polymerization and reducing inflammatory response to urate crystals.
Treatment of gout flares,Prophylaxis of gout flares,Hyperuricemia associated with gout (probenecid component)
Prophylaxis and treatment of acute gout flares,Hyperuricemia associated with gout (probenecid component)
Each tablet contains 0.5 mg colchicine and 500 mg probenecid. For gout prophylaxis, 1 tablet orally once daily, increasing to 1 tablet twice daily if needed. For acute gout flares, 2 tablets initially, then 1 tablet every 2 hours until relief or gastrointestinal symptoms occur, with a maximum of 8 tablets per flare.
One tablet (probenecid 500 mg/colchicine 0.5 mg) orally twice daily for 7 days, then one tablet daily thereafter.
Colchicine: terminal half-life 20-30 hours (up to 40-60 hours in renal impairment). Probenecid: 6-12 hours (dose-dependent, prolonged in renal disease).
Probenecid: Terminal half-life 6-12 hours (dose-dependent; prolonged at higher doses due to saturable tubular secretion). Colchicine: Terminal half-life 20-40 hours (range 9-30 hours in healthy subjects; prolonged in renal impairment up to 50-60 hours).
Colchicine is metabolized primarily by CYP3A4 and to a lesser extent by CYP2D6. Probenecid is metabolized via glucuronidation and oxidation; it inhibits renal tubular secretion of many drugs and inhibits the metabolism of some drugs.
Probenecid: hepatic via glucuronidation and oxidation; colchicine: hepatic via CYP3A4 and P-glycoprotein.
Colchicine: ~65% renal excretion as unchanged drug and metabolites; 10-20% biliary excretion. Probenecid: ~77-88% renal excretion (primarily as glucuronide conjugate); <15% biliary/fecal.
Probenecid: Renal excretion of unchanged drug and metabolites; approx. 75-95% of dose eliminated in urine, with <5% as unchanged probenecid. Colchicine: Primarily fecal excretion (about 65%) via biliary excretion; renal excretion accounts for about 20-30% of elimination, with enterohepatic recirculation.
Colchicine: 30-50% bound to albumin. Probenecid: 85-95% bound to albumin.
Probenecid: 85-95% bound to albumin. Colchicine: 30-50% bound to albumin.
Colchicine: Vd 2-4 L/kg (extensive tissue distribution, high affinity for tubulin). Probenecid: Vd 0.2-0.4 L/kg (limited extravascular distribution).
Probenecid: 0.15 L/kg (indicates distribution primarily in extracellular fluid). Colchicine: 2-8 L/kg (large Vd indicating extensive tissue distribution, particularly into leukocytes and other cells).
Colchicine: Oral bioavailability ~50% (wide interindividual variability). Probenecid: Oral bioavailability ~100%.
Probenecid: Oral bioavailability nearly complete (approx. 100%) with extensive metabolism. Colchicine: Oral bioavailability 25-50% (first-pass metabolism and P-glycoprotein efflux in gut); bioavailability listed for oral route.
Contraindicated in patients with Cr Cl < 50 m L/min. Use not recommended in severe renal impairment.
GFR 30-50 m L/min: reduce dose to one tablet daily. GFR 10-29 m L/min: one tablet every 2-3 days. GFR <10 m L/min or dialysis: contraindicated.
Avoid use in Child-Pugh class B or C due to risk of colchicine accumulation. Use with caution in mild hepatic impairment, consider reducing dose.
Child-Pugh A: no adjustment. Child-Pugh B: reduce colchicine dose by 50%. Child-Pugh C: contraindicated.
Not recommended for use in children (safety and efficacy not established).
Not recommended for pediatric use. For acute gout in adolescents, consider alternative therapy.
Use with caution due to increased risk of renal impairment and accumulation. Start at lower doses (e.g., 1 tablet daily). Monitor renal function and for myelosuppression.
Start at lowest dose (one tablet daily), monitor renal function and for toxicity due to age-related decreased renal function.
None
None.
Fatal overdoses have been reported with colchicine; do not exceed recommended dose.,Severe toxicity can occur with concomitant use of CYP3A4 or P-glycoprotein inhibitors.,Monitor renal function; dose adjustment required in renal impairment.,Hematologic toxicity (bone marrow suppression) with probenecid.,Uric acid stone formation; ensure adequate hydration and alkalinization of urine.,Drug interactions: colchicine with statins, macrolides, antifungals; probenecid with NSAIDs, penicillins, methotrexate.
Hematologic toxicity (bone marrow suppression), neuromuscular toxicity (especially with renal impairment), severe diarrhea, drug interactions (CYP3A4 and P-gp inhibitors), use caution in elderly and renal/hepatic impairment.
Hypersensitivity to colchicine or probenecid,Severe renal impairment (Cr Cl <10 m L/min),Hepatic impairment (colchicine),Blood dyscrasias (probenecid),Concurrent use of P-glycoprotein or CYP3A4 strong inhibitors (e.g., clarithromycin, ketoconazole) with colchicine
Hypersensitivity to probenecid or colchicine, severe renal impairment (Cr Cl <30 m L/min), severe hepatic impairment, concurrent use of P-gp or CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole) in patients with renal/hepatic impairment, blood dyscrasias, uric acid kidney stones.
Avoid or limit intake of high-purine foods (organ meats, anchovies, sardines, mussels, yeast extracts) as they may precipitate gout attacks. Alcohol (especially beer and spirits) increases urate production and decreases urate excretion, raising gout risk. Take with food to minimize gastrointestinal irritation.
Limit consumption of high-purine foods (e.g., organ meats, anchovies, sardines, red meat, shellfish) as they can exacerbate gout. Avoid alcohol, particularly beer and liquor, which increase uric acid production and reduce probenecid efficacy. No specific food interaction with colchicine; maintain adequate hydration.
Pregnancy Category D (probenecid) and C (colchicine). First trimester: Colchicine associated with increased risk of chromosomal abnormalities and neural tube defects. Second and third trimesters: Probenecid may cause fetal harm including nephrotoxicity and growth restriction. Colchicine may cause fetal toxicity at high doses.
First trimester: Data limited; colchicine is associated with increased risk of chromosomal abnormalities in vitro, but human studies show no consistent pattern of major malformations. Probenecid is not teratogenic in animal studies. Second and third trimesters: No evidence of fetal harm from either drug, but insufficient data. Avoid during pregnancy unless benefit outweighs risk.
Colchicine: M/P ratio 0.93; small amounts excreted, monitor infant for gastrointestinal effects. Probenecid: Not recommended; M/P ratio unknown; avoid due to potential renal effects in infant.
Colchicine is excreted into human milk in low concentrations; M/P ratio not established. Probenecid is excreted in milk in amounts likely negligible (M/P ratio ~0.5). Both considered compatible with breastfeeding, but monitor infant for diarrhea (colchicine).
Colchicine: Dose may need reduction due to increased volume of distribution and decreased clearance; monitor for toxicity. Probenecid: Dose adjustment may be needed due to increased renal clearance; monitor uric acid levels.
No specific pharmacokinetic data in pregnancy; however, increased renal clearance and volume of distribution in pregnancy may reduce probenecid and colchicine plasma concentrations. Consider dose adjustment based on clinical response and toxicity monitoring, but no standard recommendations exist.
Colchicine and probenecid combination is used for gout prophylaxis and treatment. Monitor renal function closely; probenecid is contraindicated in Cr Cl <50 m L/min. Colchicine has a narrow therapeutic index and is contraindicated in patients with hepatic or renal impairment unless dose-adjusted. Avoid concurrent use of strong CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole) which increase colchicine toxicity. Probenecid inhibits tubular secretion of many drugs (e.g., penicillins, methotrexate), increasing their levels.
Colchicine levels can increase with concurrent use of P-glycoprotein inhibitors (e.g., amiodarone, verapamil, clarithromycin) or CYP3A4 inhibitors (e.g., ketoconazole, ritonavir). Probenecid can raise plasma concentrations of penicillins, cephalosporins, and indomethacin. Monitor for colchicine toxicity (nausea, diarrhea, myopathy) especially in renal impairment; reduce dose in chronic kidney disease. Probenecid may inhibit renal excretion of drugs and can cause uricosuria, so ensure high fluid intake to prevent urate stones.
Take with food to reduce GI upset.,Drink plenty of fluids (at least 2-3 liters daily) to prevent kidney stones.,Report unusual bruising, bleeding, or signs of infection immediately.,Avoid alcohol as it increases serum urate levels and GI irritation.,Do not use this medication during a gout flare; wait until flare resolves.,Colchicine overdose can be fatal; seek emergency care if more than prescribed dose is taken.,Probenecid may cause false-positive urine glucose test with Clinitest.
Take with food or milk to reduce gastrointestinal upset.,Drink plenty of water (at least 8 glasses per day) while taking probenecid.,Colchicine can cause severe diarrhea or vomiting; stop and call your doctor if this occurs.,Avoid alcohol, which can worsen gout and interfere with probenecid's effect.,Do not start new medications (especially antibiotics, antifungal, or heart medications) without consulting your doctor due to drug interactions.,Report unexplained muscle pain, weakness, numbness, or tingling immediately (colchicine myopathy).,Keep this and all medications out of reach of children.
"Edoxaban, a direct factor Xa inhibitor, may inhibit organic anion transporters (OATs) involved in the renal excretion of probenecid, leading to increased probenecid plasma concentrations. Elevated probenecid levels can enhance its uricosuric effect and potentially increase the risk of adverse effects such as gastrointestinal disturbances and hypersensitivity reactions. Clinicians should be aware of this interaction when coadministering these agents, particularly in patients with renal impairment."
"Acemetacin, a nonsteroidal anti-inflammatory drug (NSAID) and prodrug of indomethacin, reduces renal clearance of probenecid by inhibiting tubular secretion and possibly competing for organic anion transporters. This leads to increased plasma concentrations of probenecid, prolonging its half-life and enhancing its uricosuric effect. Clinically, this interaction may result in elevated risk of probenecid toxicity, including gastrointestinal discomfort, rash, or rare blood dyscrasias, while also potentially increasing the anti-inflammatory effects of acemetacin."
"Cilostazol, a phosphodiesterase III inhibitor, can inhibit the renal tubular secretion of probenecid, a uricosuric agent, thereby decreasing its clearance and increasing its serum concentration. This elevation may potentiate the effects and toxicity of probenecid, including an increased risk of uric acid nephropathy and gastrointestinal disturbances. The interaction is of particular concern in patients with renal impairment or those receiving concurrent nephrotoxic drugs."
"Colchicine may decrease the cardiotoxic effects of Deslanoside by reducing its absorption or altering its pharmacokinetics, potentially leading to subtherapeutic digoxin levels and reduced efficacy. This interaction could increase the risk of atrial fibrillation or heart failure exacerbation in patients requiring cardiac glycoside therapy. Clinical outcomes may include loss of rate control in atrial fibrillation or decreased inotropic support in heart failure."
"Colchicine, a substrate of CYP3A4 and P-glycoprotein (P-gp), can inhibit CYP2D6 and to a lesser extent CYP3A4 at therapeutic concentrations. Fluvoxamine, a potent CYP1A2 and moderate CYP2C9/3A4 inhibitor, may have its serum concentration increased by colchicine via competition for CYP3A4 and P-gp efflux, although colchicine's inhibition of CYP3A4 is weak. This interaction could potentiate fluvoxamine's serotonergic adverse effects, including serotonin syndrome, as well as increase the risk of QT prolongation and sedation. However, clinical significance is generally low unless high doses of colchicine are used."
"Colchicine and sildenafil both utilize cytochrome P450 3A4 (CYP3A4) for metabolism. Concurrent administration can lead to competitive inhibition of CYP3A4, resulting in increased plasma concentrations of sildenafil. Elevated sildenafil levels may potentiate its vasodilatory effects, increasing the risk of hypotension, priapism, and other adverse events."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about COL-PROBENECID vs PROBENECID AND COLCHICINE, answered by our medical review team.
COL-PROBENECID is a Uricosuric that works by Colchicine binds to tubulin, inhibiting microtubule polymerization and reducing inflammatory cell chemotaxis. Probenecid inhibits renal tubular reabsorption of uric acid, increasing uric acid excretion and lowering serum urate levels.. PROBENECID AND COLCHICINE is a Uricosuric that works by Probenecid inhibits renal tubular reabsorption of uric acid, increasing its excretion; colchicine binds to tubulin, inhibiting microtubule polymerization and reducing inflammatory response to urate crystals.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between COL-PROBENECID and PROBENECID AND COLCHICINE depend on the specific clinical indication. These are both Uricosuric agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of COL-PROBENECID is: Each tablet contains 0.5 mg colchicine and 500 mg probenecid. For gout prophylaxis, 1 tablet orally once daily, increasing to 1 tablet twice daily if needed. For acute gout flares, 2 tablets initially, then 1 tablet every 2 hours until relief or gastrointestinal symptoms occur, with a maximum of 8 tablets per flare.. The standard adult dose of PROBENECID AND COLCHICINE is: One tablet (probenecid 500 mg/colchicine 0.5 mg) orally twice daily for 7 days, then one tablet daily thereafter.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining COL-PROBENECID and PROBENECID AND COLCHICINE. Probenecid inhibits OAT3-mediated renal tubular secretion of phenylbutyrate and its active metabolite phenylacetate, leading to a significant increase in systemic exposure of these metabolites. Elevated phenylacetate levels can enhance the risk of hyperammonemia, neurotoxicity, and gastrointestinal adverse effects, particularly in patients with urea cycle disorders. Concurrent use requires close monitoring for signs of toxicity and dose adjustment of phenylbutyric acid. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. COL-PROBENECID is classified as Category A/B. Pregnancy Category D (probenecid) and C (colchicine). First trimester: Colchicine associated with increased risk of chromosomal abnormalities and neural tube defects. Second and th. PROBENECID AND COLCHICINE is classified as Category A/B. First trimester: Data limited; colchicine is associated with increased risk of chromosomal abnormalities in vitro, but human studies show no consistent pattern of major malformatio. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.